Abstract

Background: Endothelin-1 (ET-1) both stimulates nociceptors and sensitizes them to noxious stimuli, an effect probably mediated by the $\text{ET}_A$ receptor ($\text{ET}_A$R) expressed in sensory neurons. The cellular mechanisms of this ET-1-mediated effect are only poorly understood. TRPV1, the heat-, pH- and capsaicin-sensitive cation channel already known to be modulated by a number of cellular mediators released in response to noxious stimuli and during inflammation, is a potential target for the action of ET-1.

Results: We studied the effects of ET-1 on TRPV1 in sensory neurons from the dorsal root ganglion (DRG) and in HEK293 cells coexpressing TRPV1 and the $\text{ET}_A$R. Specific $^{125}$I-ET-1 binding sites (817 ± 92 fmol/mg) were detected in membrane preparations of DRG with an $\text{ET}_A$R/$\text{ET}_B$R ratio of 60:40. In an immunofluorescence analysis, coexpression of TRPV1 and the $\text{ET}_A$R was found in a subpopulation of primary sensory neurons. ET-1 strongly potentiated capsaicin-induced TRPV1 currents in some neurons, and in HEK293 cells coexpressing TRPV1 and the $\text{ET}_A$R. Weaker potentiation was observed in HEK293 cells coexpressing TRPV1 and the $\text{ET}_B$R. $\text{ET}_A$R activation also increased responses to low pH and heat. In HEK293 cells, strong potentiation of TRPV1 like that induced by ET-1 via the $\text{ET}_A$R could be induced by PKC activation, but not with activators of the adenyllyl cyclase or the PKA pathway. Furthermore, inhibition of PKC with bisindolylmaleimide X (BIM X) or mutation of the PKC phosphorylation site S800 completely prevented $\text{ET}_A$R-mediated potentiation.

Conclusion: We conclude that ET-1 potentiates TRPV1 by a PKC-dependent mechanism and that this could play a major role in the algogenic and hyperalgesic effects of ET-1 described in previous studies.
Background
Endothelin is one of many local mediators that are important in pain generation and the modulation of nociceptor responsiveness to painful stimuli. The endothelins, ET-1, ET-2 and ET-3, are vasoactive peptides, originally cloned from endothelial cells [1], but also produced by other cell types, including some tumor cells [2-5]. Endothelins act on ETA and ETB receptors (ETARs and ETBRs) [6,7], both G protein-coupled receptors that can activate multiple G protein types and influence various signaling pathways [8].

ET-1 injection excites nociceptors [9,10] and induces nocifensive behavior in animals [11-13], and severe pain and tactile allodynia in humans [14]. ET receptor antagonists have been reported to reduce neuropathic and inflammatory pain, and pain in patients with metastatic prostate cancer (see [15,16] for reviews). Given the number of reports on the involvement of ET-1 in nociception, relatively little is known about the signaling cascade and effectors that lead to the nociceptive responses to ET-1 in primary sensory neurons.

Activation of the ETAR, which is expressed in sensory neurons [17], results in small increases in $[Ca^{2+}]_i$, in a sensory neuron-derived cell line [18] and DRG neurons [19], and in a protein kinase C(PKC)-ε-mediated potentiation of Ca$^{2+}$ responses to capsaicin [19]. The increased responsiveness of sensory neurons may result from an ETAR-mediated lowering of the threshold for activation of tetrodotoxin (TTX)-insensitive Na$^+$ channels [20], but may involve other effectors. One possibility is that ET-1 affects other channels like the nonselective cation channel TRPV1, an integrator of a number of noxious stimuli, including heat (> 42°C), capsaicin, endocannabinoids and H+ [21], which is essential for thermal hyperalgesia in inflammation [22,23]. TRPV1 activation results in depolarization and excitation of sensory neurons. In a preliminary conference report we showed that activation of the ETAR potentiates TRPV1 responses to capsaicin in HEK293 cells [24]. A number of modulators sensitize nociceptors by potentiating TRPV1 responses [25-30]. Possible mechanisms involved in potentiation are phosphorylation via PKC-ε [31] and protein kinase A (PKA) [32,33], disinhibition of TRPV1 by hydrolysis of phosphatidylinositol bisphosphate (PIP$_2$) [28], or modulation via phophatidylinositol-3-kinase and extracellular signal-related kinases 1/2 [34].

In this study, we investigated ET receptor expression in DRG and, using the patch clamp technique, the effects of ET-1 on responses to capsaicin in DRG neurons. A subpopulation of neurons responded to ET-1 with a potentiation of the capsaicin-mediated responses. To investigate the signaling pathways involved in potentiation, we studied the effects of ET-1 in HEK293 cells coexpressing the ETAR and TRPV1.

Results
Endothelin receptors in dorsal root ganglion neurons
The expression of endothelin receptor subtypes in the rat lumbar DRG was analyzed in binding experiments using $^{125}$I-ET-1 as the radioligand. Saturation binding analysis of membranes derived from isolated lumbar DRG (L4 – L5) revealed a maximal binding capacity of 817 ± 92 fmol/mg (mean ± SD of three measurements performed in duplicate). When the ET$_A$-selective antagonist BQ123 or the ET$_B$-selective agonist IRL1620 were used as competing ligands (to determine the amount of ET$_A$R or ET$_B$R expression), binding capacities of 503 ± 115 and 313 ± 113 fmol/mg protein were obtained, respectively. Thus, both ET$_A$Rs and ET$_B$Rs are expressed in the rat DRG with an expression ratio of 60:40.

In an immunofluorescence analysis, we further studied the distribution of ET$_A$Rs and ET$_B$Rs in tissue sections of lumbar DRG. To probe whether ET$_A$Rs and ET$_B$Rs are expressed in small sensory neurons that express TRPV1, we performed double staining experiments using affinity-purified antibodies against ETARs or ETBRs in conjunction with antibodies against TRPV1. The data show that ET$_A$Rs are widely expressed in small and medium-to-large diameter neurons, and, in particular, in TRPV1-expressing small sensory neurons (Fig. 1A). Controls with preimmune serum showed a weak uniform staining of all neurons (not shown). Coexpression of the ET$_A$R with TRPV1 was found in 31 of 66 TRPV1-positive DRGs (47%). ET$_B$R expression in DRGs was, if present, relatively weak (Fig. 1B), and not easy to distinguish from unspecific staining (not shown). The staining with the ET$_B$R antibody showed a different pattern from that of the ET$_A$R and TRPV1 antibodies and surrounded the perikarya, possibly reflecting expression in satellite cells. More prominent staining with the ET$_B$R antibody was observed when analyzing the axonal extensions of DRG, where the cells stained by the ET$_B$R antibody were costained by antibodies directed against the S100 antigen (Fig. 1C), indicating they are glia. In contrast, for the ET$_A$R no expression was found in glial cells (data not shown). Thus, ET$_A$Rs are found in sensory neurons, including TRPV1-positive small diameter neurons, whereas ET$_B$Rs are mainly found in glial cells. Our data on ETR expression in sensory neurons are consistent with previous reports [17,35], which also demonstrated ET$_A$R expression in neurons, frequently in small neurons together with calcitonin gene-related peptide [17], a marker of a subpopulation of C fibers. These studies also demonstrated ET$_A$R expression in DRG satellite cells and nonmyelinating Schwann cells, but not in DRGs.
Effects of ET-1 in isolated sensory neurons

A low concentration of capsaicin (10 nM) evoked currents through TRPV1 in a subpopulation of DRG neurons. In the Ca\(^{2+}\)-free extracellular solutions used to minimise the Ca\(^{2+}\)-dependent component of desensitization, repetitive applications of capsaicin activated currents which were either stable or which declined slowly. In 9/30 capsaicin-sensitive neurons (30%), application of ET-1 (100 nM) for 30 or 60 s prior to the application of 10 nM capsaicin resulted in a large increase in the capsaicin-induced current (Fig. 2A). On average, currents were increased 14.7 ± 4.1-fold (mean ± SEM, n = 8) when the first capsaicin-elicited response after ET-1 treatment was compared to that before ET-1 addition. The potentiation of the capsaicin responses by a single application of ET-1 was transient; the amplitude of the capsaicin-activated current declined to different degrees in response to repetitive stimulation in the six neurons in which three or more capsaicin responses could be elicited after ET-1 application. However, as shown in Figure 2A, potentiation often persisted for several minutes. In 5/9 neurons that responded to ET-1 with a potentiation of capsaicin-activated currents, ET-1 alone also transiently activated an inward current with a wide range of amplitudes (between -2.0 and -69.3 pA/pF, mean: -25.5 ± 12.3 pA/pF, n = 5) at -60 mV (Fig. 2B). Activation and decay of the ET-1-activated current was rapid. The cells that responded to ET-1 with a potentiation of capsaicin-activated currents could not be distinguished from the non-responsive cells on the basis of their size. Their capacitances, indicative of the cell surface area, were 35.3 ± 5.9 pF (n = 8) and 39.1 ± 3.7 pF (n = 21), respectively. In 13 of the 21 cells that did not respond to ET-1, we subsequently tested for the ability of bradykinin (1 µM) to potentiate capsaicin (10 nM)-activated TRPV1 currents. In 6/13 cells, bradykinin application resulted in a potentiation of capsaicin-activated currents through TRPV1 (16.5 ± 7.6-fold, n = 6), which closely resembled that induced by ET-1 (data not shown). It was notable that responses of DRGs to ET-1 were mainly observed on the day of preparation, or on the day after preparation. Neurons cultured for longer rarely responded to ET-1, but did respond to bradykinin, suggesting that in cultured DRGs the expression of ET receptor subtypes might be down regulated or that there is an impairment in the efficiency of coupling to downstream signaling cascades. Loss of receptors during culture may also explain the lower percentage of cultured capsaicin-sensitive neurons that respond to ET-1, compared to the percentage of DRGs coexpressing TRPV1 and ET\(_{AR}\) in sections of ganglia.

Effects of ET-1 on HEK293 cells transiently transfected with TRPV1 and the ET\(_{AR}\) or ET\(_{BR}\) receptor

Owing to the small fraction of neurons that responded to ET-1, the regulation of TRPV1 by ET-1 was analysed in HEK293 cells transiently co-transfected with plasmids encoding TRPV1-YFP and the ET\(_{AR}\) or ET\(_{BR}\). HEK293 cells co-expressing the ET\(_{AR}\) and TRPV1 responded to 10 nM capsaicin with currents that displayed the characteristic outwardly-rectifying IV-relation of TRPV1 (Fig. 3A, B). ET-1 application (100 nM) for 30 s or 1 minute resulted in a large potentiation of capsaicin-activated currents through TRPV1 (Fig. 3A – C), like that in sensory neurons. Currents recorded during the first response to capsaicin directly after ET-1 application were increased 8.3 ± 1.5-fold (n = 10), those in response to the second capsaicin application, 2.5 minutes after ET-1 treatment, 10.7 ± 2.0-fold (n = 9). In addition, in most cells, ET-1 application resulted in the slow activation of a current, particularly in the outward direction, with the characteristics of TRPV1 (Fig. 3A, B). However, none of the cells displayed a rapid, transient current like that seen in DRGs, an indication that the ET-1-activated current in DRGs may be mediated by a different channel.

In ET\(_{AR}\)-expressing cells, application of ET-1 also potentiated currents activated by low pH or by heat (Fig. 3D – I). H\(^+\)-activated TRPV1 currents were evoked by application of a solution of pH 5.1, a pH which produces a submaximal TRPV1 activation, preceded by the application of a
solution of pH 6.8 to desensitize endogenous acid-sensing ion channels (ASICs; Fig. 3D) [36]. Application of ET-1 resulted in a 9.9 ± 1.3-fold (n = 12) potentiation of the first response to pH 5.1 after ET-1 application (Fig. 3D – F), and a significant potentiation of subsequent responses (Fig. 3D, F). Current responses of TRPV1 to heat were recorded upon raising the temperature from room temperature to 44°C (Fig. 3G). In controls, consecutive responses had similar amplitudes (Fig. 3G, left). ET-1 augmented the responses to the increase in temperature (2.5 ± 0.6-fold, n = 10, for the first response after ET-1, Fig. 3I) and, as illustrated for the experiment in Fig. 3G, 3H, shifted the threshold for TRPV1 activation to lower temperatures (Fig. 3I).

HEK293 cells transfected with the same amounts of TRPV1 and the ETAR showed a less prominent ET-1-induced potentiation of capsaicin-stimulated TRPV1 currents when compared to that elicited by the ETBR (Fig. 4). The first and second responses after ET-1 application were 2.9 ± 0.8-fold and 2.7 ± 0.5-fold (n = 5) that of the control, respectively.

### Role of protein kinases in the ET<sub>A</sub> receptor-mediated potentiation of TRPV1

Both ET receptor subtypes couple to G proteins from different families and each of the receptor types has its own distinct profile of G proteins that can activate. The ET<sub>A</sub>R stimulates G proteins of the G<sub>q</sub>, G<sub>q13</sub>, and G<sub>12/13</sub> families, the ET<sub>B</sub>R activates G proteins of the G<sub>q</sub> and G<sub>i</sub> families e.g. [37-40]. To investigate the signalling pathways activated and possibly involved in the modulation of TRPV1 in HEK293 cells, we studied cAMP and inositol phosphate formation in HEK cells stably expressing the ET<sub>A</sub>R or ET<sub>B</sub>R. ET-1 induced 22 ± 2.5- and 18 ± 2.0-fold increases in inositol phosphate formation via ET<sub>A</sub>Rs and ET<sub>B</sub>Rs, respectively (Table 1). For HEK cells expressing the ET<sub>A</sub>R, a 34 ± 10.6-fold increase in cAMP levels was noted. Cells expressing the ET<sub>B</sub>R did not show any ET-1-induced increase in cAMP.

From the data presented above, stimulation of the G<sub>A</sub>-coupled ET<sub>A</sub>R in HEK293 cells could potentiate TRPV1 by a PLCß-mediated breakdown of PIP<sub>2</sub> or by the production of DAG and activation of PKC. Alternatively, TRPV1 potentiation could be mediated by the activation of PKA. We therefore studied the effects of PKC and adenylyl cyclase (AC)/PKA activation on capsaicin-mediated TRPV1 activation, and compared these with ET-1/ET<sub>A</sub>R-mediated effects on TRPV1 activity. Application of the phorbol ester, phorbol myristate acetate (1 µM), for 1 minute before the addition of capsaicin (10 nM) resulted in a clear and strong potentiation of the capsaicin responses that closely resembled the potentiation seen with ET-1 (Fig. 5). In contrast to activation of PKC by PMA, the activation of AC with forskolin (50 µM, Fig. 5) or treatment with the membrane-permeable cAMP analog, dibutyryl cAMP (dbcAMP; 5 mM), had comparatively weak effects or no effect on TRPV1 currents, respectively. After 1.5 minutes of treatment, forskolin increased currents 1.5 ± 0.1-fold (n = 4), but the effect after 4 minutes of forskolin treatment was not significant. Similarly, dbcAMP had no significant effect on current responses to capsaicin; they were 0.97 ± 0.11-fold (n = 4, p = 0.802) and 1.5 ± 0.5-fold (n = 4, p = 0.357) of the control, after 1.5 and 4 minutes of dbcAMP application, respectively.

To analyse the role of PKC activation in ET-1-mediated potentiation of TRPV1, we tested the effect of the PKC inhibitor BIM X on the potentiation of capsaicin-induced TRPV1 currents in response to ET-1. Potentiation was completely prevented by a 2 minute incubation with BIM X (500 nM) prior to the ET-1 application (Fig. 6A). Control experiments performed in parallel on the same days with cells transfected at the same time showed strong

---

**Figure 2**

**Potentiation of capsaicin-activated currents in dorsal root ganglion neurons by ET-1.** A, Recording of current at -60 mV showing responses to repetitive applications of capsaicin (10 nM) in a Ca<sup>2+</sup>-free extracellular solution. Application of ET-1 (100 nM) at the time indicated by the bar resulted in a small increase in current during the ET-1 application and a large potentiation of the capsaicin-activated currents. B, Results of a similar experiment to that in A which shows a larger current response to ET-1 application. C, Bar graph summarising the potentiation of capsaicin responses by ET-1 (100 nM) in ET-1-responsive rat DRG neurons. Control is the normalized capsaicin response before ET-1 application, after ET-1 the first (n = 9, p = 0.0066) and second (n = 8, p = 0.017) normalized responses after ET-1 application.**
Figure 3
Potentiation of TRPV1 currents by ET-1 in HEK293 cells cotransfected with TRPV1 and the ETAR. A – C, Potentiation of capsaicin-activated currents by ET-1. A, Recording of current at -60 mV showing the potentiation of responses to capsaicin (10 nM) by the application of ET-1 (100 nM). B, IV-relationships recorded at the times indicated by the numbers 1 – 4 in A. C, Bar graph summarizing the potentiation of TRPV1 responses to capsaicin by ETAR activation in HEK293 cells. The bars show the normalized control response prior to ET-1 application and the normalized first (n = 10, p = 0.0009) and second (n = 9, p = 0.0012) responses after ET-1 application. D – F, Potentiation of H+-activated currents by ET-1. D, ET-1 increased the amplitude of TRPV1 responses to pH 5.1. Currents were recorded at -60 mV and applications of pH 5.1 preceded by a solution of pH 6.8 to prevent the activation of endogenous ASICs. E, IV-relationships recorded at the times indicated by numbers in D. F, Bar graph summarizing the potentiation of the TRPV1 response to pH 5.1 by ET-1, and showing the normalized response before ET-1, and the first (n = 12, p < 0.0001) and second (n = 9, p = 0.0069) responses after ET-1. G – J, Potentiation of heat-activated currents through TRPV1 by ET-1. G, Current recordings at -60 mV (upper traces) showing consecutive responses of a control cell to heating to 44°C (left), and responses from a cell treated with ET-1 after the first response to heat (right). The lower traces show the temperature recorded in the chamber close to the cell. H, I-V relationships recorded at the times indicated by the numbers in G. I, Bar graph summarizing the potentiation of the normalized first (n = 10, p = 0.0232) and second (n = 7, p = 0.0233) responses to heat after ET-1. J, Plot of the current-temperature relationships for the control response (filled squares) and the second response after ET-1 (open squares) from the experiment in G.
potentiation (Fig. 6B). In contrast to the results after PKC inhibition, potentiation still occurred after treatment with the protein kinase inhibitor H89 (5 µM, n = 4), which at this concentration most strongly inhibits PKA, and was not significantly different from that without H89 (Fig. 6).

To confirm the pivotal role of PKC-mediated phosphorylation in the modulation of TRPV1 by ET-1 using an independent approach, we employed a mutant of TRPV1 which does not show PKC-mediated potentiation. The PKC phosphorylation sites involved in PKC-mediated enhancement of capsaicin-activated currents through TRPV1 have been localized to S502 and S800 [41,42]. Mutation of either site to alanine leads to a very strong reduction in sensitization of currents by PMA [41,42] and by mediators that act via the Gq/11-coupled metabotropic P2Y1 receptor leading to an activation of PKC [41]. We therefore tested the effects of ETαR activation on the TRPV1 mutant TRPV1-S800A. The ETαR was coexpressed with YFP-tagged TRPV1-S800A in HEK293 cells. The mutant TRPV1-S800A differed from wild type TRPV1 in that currents tended to increase with consecutive responses, rather than decrease (compare the first and second response to capsaicin in Fig. 7A). In contrast to wild type TRPV1, no significant potentiation of capsaicin-activated currents was observed on application of ET-1 (Fig. 7). It is unclear whether the slight increase after ET-1 in Fig. 7A results from run-up of channel currents or from a very small potentiation that persisted in the mutant. The inability to observe an effect does not result from the briefer capsaicin application than that for the wild type because the application was continued until the current response was close to a plateau (Fig. 7A, lower trace). It is clear, however, that the strong stimulatory effect of ETαR activation is lost following mutation of the PKC phosphorylation site, consistent with sensitization resulting from PKC-mediated phosphorylation.

**Discussion**

We show here that DRG neurons mainly express ETαRs and that their expression partially overlaps with the expression of TRPV1. We also show that ET-1 potently modulates the functional activity of TRPV1 in a subpopu-
lution of sensory neurons and in HEK293 cells co-expressing the ET$_A$R and TRPV1. A significant modulation of TRPV1 activity was also found for HEK293 cells co-expressing TRPV1 and ET$_B$Rs.

Even though the ET$_A$R can stimulate pathways leading to both PKA and PKC activation, receptor-mediated potentiation of TRPV1 in HEK293 cells was predominantly mediated by PKC. Evidence for this is that ET-1 effects were completely inhibited by the PKC inhibitor BIM X, and prevented in the PKC phosphorylation site mutant TRPV1-S800A. There is also a strong similarity between the extent of potentiation by ET-1 and that elicited by the PKC-activating phorbol ester PMA. In contrast to the effects of PKC activation and inhibition, the effects of PKA activation by forskolin were comparatively weak, and dBcAMP had no significant effect. Potentiation by ET-1 also persisted in the presence of H-89, an inhibitor of PKA. In addition, some potentiation was observed with the ET$_A$R which did not increase cAMP. These results indicate that, under the conditions used, i.e. in the absence of extracellular Ca$^{2+}$, ET-1-mediated potentiation is unlikely to occur via $G_s$ and AC, nor to a great extent via PKC-mediated activation of AC. Because the cAMP/PKA pathway acts, at least partly, by decreasing Ca$^{2+}$-dependent desen-

sitation [32,43], we cannot rule out that this pathway provides an additional component of potentiation of TRPV1 by ET-1 at physiological Ca$^{2+}$ concentrations. Our work lends support to a recent study showing that PKC-$\varepsilon$ is involved in the ET-1-mediated enhancement of capsaicin-induced Ca$^{2+}$ increases in sensory neurons, but which did not show that TRPV1 is the target for PKC-$\varepsilon$-mediated phosphorylation [19]. Our observation is also in line with the finding that S800 is crucially involved in PMA-mediated sensitization of TRPV1 via PKC-$\varepsilon$ [44]. From our data, we cannot rule out that different pathways may be involved in the responses to ET-1 in sensory neurons, but there is a striking similarity between the effects in DRGs and in HEK293 cells. The evidence for an involvement of PKC in potentiation by ET-1 supports studies showing an involvement of PKC in potentiation of TRPV1 by bradykinin via B$_2$ receptors [26,27,31], ATP via $G_q$-coupled P$_2Y_1$ receptors [41,45], the chemokine CCL$_3$ via CCR$_1$ [46], 5-HT via 5-HT$_2$ receptors [47], and in some of the effects of prostaglandins via EP$_3$ or IP receptors [48], but contrasts with that showing that the effects of bradykinin and NGF result from PLC-mediated release of TRPV1 from inhibition by PIP$_2$ [28,49]. The increase of TRPV1 currents in response to PKC activation in sensory neurons most likely results from a phosphorylation-induced increase in the activity of channels at a given agonist concentration [50], but has also been attributed to an increased recruitment of intracellularly-stored vesicles carrying TRPV1 to the plasma membrane [51].

In DRG neurons, we observed two effects of ET-1: potentiation of responses to capsaicin and, in a smaller population of neurons, the activation of an inward current. These effects are very similar to those of bradykinin, which also activates an inward current, most likely a cation current, in some sensory neurons [26,52,53], and potentiates currents through TRPV1 [26,27,31]. It remains unclear whether the channel activated by bradykinin is TRPV1 because not all heat-sensitive neurons with temperature thresholds of 42°C, characteristic for TRPV1, show a current response to bradykinin [26]. On the other hand, high concentrations of bradykinin can shift the temperature threshold of TRPV1 sufficiently to produce a current at room temperature [27]. The inward current activated by ET-1 was not characterized directly, but it differed from TRPV1 currents in the absence of current noise for currents of comparable amplitudes, and there was no link between the amplitude of the ET-1-activated and capsaicin-activated currents. Other possible candidates for the ET-1-activated channel include other cation channels, like e.g. TRPA1, which has been shown to be activated by bradyki-

nin [54]. It is also notable that in HEK293 cells co-transfected with TRPV1 and ET$_B$Rs or ET$_A$Rs, ET-1 did not induce a rapidly activating and inactivating inward current like that in DRG neurons, but did result in a small
slow increase in an outwardly-rectifying current that resembled TRPV1. Thus, the molecular basis and nature of the fast inward current seen in DRG neurons in response to ET-1 remains to be clarified.

Our data at the cellular level support a role of potentiation of currents through TRPV1 in ET-1-induced excitation of nociceptors by increasing their sensitivity to algogenic stimuli. Furthermore, ET-1 could produce an initial transient excitation of some neurons by the activation of an inward current. Previous studies have postulated that part of the effects of ET-1 on nociception occur via modulation of TTX-resistant Na+ channels [20] shifting their potential dependence of activation to more negative membrane potentials leading to enhanced excitability of the sensory neurons. Effects on Na+ channels have been observed with the hyperalgesic modulators PGE2, 5-HT, epinephrine and adenosine (for reviews see [55,56]), and may be mediated by PKA or PKC activation [57]. Thus, the actions of ET-1 in sensory neurons involve contributions of Na+ channels and TRPV1, and may be mediated by both PKA and PKC. By its concerted actions on TRPV1 and Na+ channels, ET-1

---

**Figure 6**

**Protein kinase C inhibitors, but not protein kinase A inhibitors prevent the potentiation of TRPV1 by ET-1.**

A, Current trace from an experiment in which the PKC inhibitor BIM X (500 nM) was applied immediately prior to stimulation with ET-1 (100 nM) illustrating that BIM X treatment prevented potentiation by ET-1. B, Bar graph summarizing the effects of ET-1 on the first response to capsaicin after ET-1 in the absence \( (n = 6, p = 0.0156) \) and presence of BIM X \( (n = 7, p = 0.8964) \). C, Trace showing ET-1 potentiation of capsaicin-activated currents in the presence of the PKA inhibitor H-89. D, Bar graph summarizing the effects of ET-1 on the first \( (n = 4, p = 0.0953) \) and second \( (n = 4, p = 0.0275) \) capsaicin responses after treatment with H-89. Cells were cotransfected with TRPV1-YFP and the ETAR.
could increase the depolarization of sensory endings in response to noxious stimuli and concomitantly reduce the threshold for activation of a population of Na⁺ channels.

The effects of ET-1 on nociception are complex. Different experimental models have been used to study the role of ET-1 in nociception, and receptor subtype-specific agonists and antagonists to identify the ET receptor subtype mediating the effects. The pronociceptive actions of ET-1 have been reported to involve either ET₃Rs [9,10,58-62] or ET₄Rs [63,64], or both ET₃Rs and ET₄Rs [12,65,66]. Our results indicate that the ET₃R is expressed in sensory neurons and could contribute to the algogenic effects of ET-1 by sensitizing TRPV1. This suggestion is supported by a recent study on mouse DRGs which showed that the Ca²⁺ release in response to ET-1, and the potentiatory effect of ET-1 on capsaicin-induced Ca²⁺ responses are mediated exclusively by ET₃Rs [19]. Even though the ET₄R is able to potentiate TRPV1 in HEK293 cells, the low level of ET₄R expression in DRG neurons indicates that the algogenic effects of ET₄R agonists [12,64] and the analgesic effects of ET₄R antagonists [63-66] are more likely to result from indirect effects on the ET₄R in Schwann and other glial cells where receptor expression is high [17]. It is difficult to extrapolate from data obtained on single isolated neurons to the situation in vivo, but our results could explain the excitatory effects of ET-1 injection on nociceptors and some of the amplification of responses to thermal and mechanical stimuli. The rapid inward current, if occurring in the periphery, could rapidly excite some ET receptor-expressing nociceptive neurons. Thereafter, the potentiating of TRPV1 could be responsible for the excitation, and for the hyperalgesia and allodynia seen after ET-1 application. Potentiation of TRPV1 with high ET-1 concentrations occurs rapidly and, although it decreases with time, by extrapolating our data (e.g. those in Fig. 2A) can probably persist for several tens of minutes. It is more difficult to explain the TRPV1-mediated prolongation of tactile allodynia in response to low ET-1 concentrations where a role of TRPV1 is only significant at times longer than 30 minutes after ET-1 application [67]. While the role of the ET₃R in the action of ET-1 on nociception is relatively clear, the role of the ET₄R is less well understood. The ET₄R in glial cells and possibly in neurons is likely to have pronociceptive effects, whereas the ET₄R in keratinocytes has been reported to mediate the analgesic effects of ET-1 and ET₄ agonists by inducing the release of β-endorphin [68].

**Conclusion**

Our results show that ET-1 potentiates TRPV1 via a PKC-mediated effect and we suggest that this could be responsible for a major part of the pain-producing and hyperalgesic effects of ET-1 observed in previous studies.

**Methods**

**Isolation and culture of DRG neurons**

Dorsal root ganglia (DRG) were isolated as described recently [69]. In brief, DRG from lumbar segments L4 – L5 of male Wistar rats were isolated and placed in Minimal Essential Medium (MEM, Biochrom AG, Berlin, Germany) at 4°C. Thereafter, they were sequentially digested with collagenase (type II; 3 mg/ml) for 50 min at 37°C, and trypsin (type I; 0.25 mg/ml) for 10 min at 37°C. After careful mechanical dissociation, cells were washed twice and resuspended in fresh medium supplemented with 10% horse serum, 50 ng/ml NGF, 50 U/ml penicillin and 50 µg/ml streptomycin. Neurons were seeded on poly-l-lysine-coated glass coverslips in 6-well culture plates 4 – 36 h before the experiments. Neurons were kept at 37°C in an atmosphere of 5% CO₂.
Generation of plasmids encoding mutant TRPV1

To investigate the role of PKC-mediated phosphorylation of TRPV1, a plasmid was generated, which encodes a mutant TRPV1 in which serine 800 is replaced by alanine (TRPV1-S800A). Site-directed mutagenesis was performed with the QuickChange mutagenesis kit (Stratagene, La Jolla, CA), using a plasmid encoding a rat TRPV1-YFP fusion protein [70] and appropriate sense and antisense oligonucleotides spanning the mutated triplet and 15 flanking nucleotides. The construct was verified by DNA sequencing.

HEK culture

HEK293 cells were cultured in MEM-Earle medium (Biochrom), supplemented with 10% (v/v) fetal calf serum (Gibco/Invitrogen, Karlsruhe, Germany) and 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were plated onto glass cover slips 24 – 48 h prior to transfection. The cells were transiently transfected with 1 µg of the plasmid pTRPV1-YFP [70] and 2 µg of the plasmid pETα-myc DNA [71] or the plasmid containing the FLAG-tagged ETβ DNA [71] using 6 µl of FuGENE 6 Transfection Reagent (Roche Diagnostics, Mannheim, Germany) in 94 µl OptiMEM medium (Gibco/Invitrogen) per 85 mm dish. In some experiments, cells were transfected 1 – 2 days after plating into 35 mm dishes using 9 µl TransIT (Mirus, Madison, WI) in serum-free MEM-Earle medium, subsequently trypsinized and plated onto glass coverslips 2 days after transfection. No differences were observed between results obtained with the two methods. Electrophysiological experiments were performed 24 – 72 h after transfection.

Immunofluorescence analysis

Immunofluorescence analysis was performed as described recently [69]. Freshly isolated DRG were embedded in Tissue-Tek compound (OCT, Miles Inc., Elkhart, USA) and frozen. Consecutive sections (9 µm) were prepared with a cryostat and mounted onto gelatin-coated slides. To prevent non-specific binding, the sections were incubated for 60 min in PBS containing 0.3% Triton X-100, 1% BSA, 4% goat serum, and 4% horse serum (block solution). The sections were then incubated overnight at 4°C with a guinea pig polyclonal antibody against TRPV1 (1:1,000; Chemicon, CA, USA) or S100 Antigen (1:200; Abcam, Cambridge, UK) in combination with a peptide-derived rabbit polyclonal antibody directed against the C terminus of the ETαR (1:100) (Plant et al., 2006) or against the N terminus of the ETβR (1:100) [71]. The tissue sections were washed with PBS and then incubated with Texas red-conjugated goat anti-rabbit antibody and FITC-conjugated donkey anti-guinea pig antibody. Thereafter, sections were washed with PBS, mounted in vectashield (Vector Laboratories, Burlingame, CA, USA) and viewed with a Zeiss 510 laser scanning microscope (Zeiss, Oberkochen, Germany).

CAMP and inositol phosphate measurements

Determination of inositol phosphates and of cAMP was performed as described previously [72]. In brief, HEK293 cells stably expressing ETARs or ETBRs were seeded onto 24-well plates (100,000 cells/well). For inositol phosphate determination, cells were incubated the following day with 74 kBq/ml myo-[2-3H]inositol (specific activity 370 – 740 GBq/mmol; Amersham Biosciences) for 20 h at 37°C. Cells were then washed with DMEM, 10 mM HEPEs, 0.5% BSA, 10 mM LiCl, and finally stimulated with buffer or increasing concentrations of ET-1 (10 pM to 100 nM) for 60 min at 37°C. Cells were then lysed with 0.1 M NaOH, and inositol phosphates isolated from cleared supernatants by anion exchange chromatography.

For the determination of cAMP, cells were washed with 1 ml of stimulation medium (DMEM without fetal calf serum, supplemented with 10 mM HEPEs, 0.5% BSA, 0.25 mM 3-isobutyl-1-methylxanthine) and incubated for 30 min at 37°C with buffer or increasing concentrations of ET-1 (10 pM to 100 nM). Cells were extracted with 750 µl of 0.1% trifluoroacetic acid, 0.005% Triton X-100 for 30 min at 4°C. After acetylation of the samples, the cAMP content was determined using 125I-cAMP-tyrosylmethyl-ester (10,000 cpm, specific activity 81.4 TBq/mM, Biotrend, FRG) and polyclonal rabbit anti-cAMP-antibody (final dilution 1:1,600,000). After an overnight incubation at 4°C, the antibody-bound fraction was precipitated, and the radioactivity of the precipitate was determined in a β-counter.

125I-ET-1 binding analysis

Binding analysis was performed as described [73,74]. In brief, membranes (5 µg) of DRGs were incubated in a final volume of 200 µl Tris/BAME buffer with increasing concentrations of 125I-ET-1 (18 to 1000 pM) in the absence or presence of unlabelled ET-1 (1 µM) (to detect ETαR and ETβR) for 2 hours at 25°C. The ratio of ETα and ETβR expression was determined by 125I-ET-1 saturation binding analysis using ET-1 (1 µM, total binding), IRL1620 (1 µM, ETβR-specific binding) or BQ123 (10 µM, ETαR-specific binding) as competing ligands. The samples were then transferred onto GF/C filters (Whatman International Ltd., Maidstone, UK), and washed twice with PBS using a Brandel cell harvester. Radioactivity was determined in a γ-counter. Data were analyzed with RadLig Software 4.0 (Cambridge, UK).

Patch clamp recordings

Recordings of whole cell currents from single cells were made with an EPC-7 or EPC-10 amplifier using Pulse software (HEKA, Lambrecht, Germany) as described previ-
ously [75]. Experiments were performed using the standard whole cell mode of the patch clamp technique. Cells were held at a potential of -60 mV and the current recorded using XChart (HEKA). In HEK293 cells, ramps from -100 to +100 mV with a duration of 400 ms were applied at a frequency of 0.2 Hz. Ramp data were acquired at a frequency of 4 kHz after filtering at 1 kHz.

The standard pipette solution contained 100 mM CH₃O₃SCs (cesium methane sulfonate), 25 mM CsCl, 3 mM MgCl₂, 2 mM Na₂ATP, 3.62 mM CaCl₂, 10 mM EGTA, 30 mM HEPES (pH 7.2 with CsOH). Pipette tips were filled with the same solution without ATP to avoid the activation of purinergic receptors prior to seal formation. The standard extracellular solution contained: 140 mM NaCl, 5 mM CsCl, 2 mM CaCl₂, 1 mM MgCl₂, 10 mM glucose, 10 mM HEPES (pH 7.4 with NaOH). For Ca²⁺-free solutions, Ca²⁺ was omitted and 0.5 mM EGTA added. Experiments were performed at room temperature 20 – 25°C. Solutions were applied by bath perfusion. In most cases, with the exception of Fig. 2B, which was not used for quantification of the response, capsaicin was applied until currents approached a steady state value. In experiments on the effects of heat, bath temperature was measured using a thermistor placed close to the cell studied and recorded using XChart. The test solution was preheated to appropriate temperatures using a water jacket connected to a water bath.

Competing interests
The author(s) declare that they have no competing interests.

Authors' contributions
TP conceived and designed the study, performed the electrophysiological experiments, analyzed the data and drafted the manuscript. CZ isolated the DRGs for immunohistochemical work and binding experiments, established primary cultures and perfomed part of the cAMP and inositol phosphate experiments. FK performed electrophysiological experiments and analyzed the data. SSM performed the immunohistochemistry. JE conducted binding experiments with membrane preparations of DRGs. MS provided rTRPV1-YFP and generated the TRPV1-S800A mutant. JF conducted part of the cAMP and inositol phosphate experiments, and performed analysis of cAMP and inositol phosphates from cell extracts. CS supervised the part of the study on DRGs. AO conceived and designed the study, performed laser scanning microscopy, supervised binding experiments and respective analysis, and drafted the manuscript.

All authors read and approved the manuscript.

Acknowledgements
This work was supported by grants from the DFG and Fonds der Chemischen Industrie. We thank Inge Reinsch and Nadine Albrecht for technical assistance.

References
1. Yangisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsu Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
2. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Colligan JE, Kehrl JH, Fauci AS: Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990, 172:1741-1748.
3. Gökkin A, Gibson SJ, Ibrahim BN, Legon S, Bloom SR, Yangisawa M, Masaki T, Varndell IM, Polak JM: Endothelin 1, an endothelium-derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. Proc Natl Acad Sci U S A 1989, 86:7634-7638.
4. MacCumber MW, Ross CA, Snyder SH: Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc Natl Acad Sci U S A 1990, 87:2359-2363.
5. Nelson JB, Hedican SP, George DJ, Reddi AH, Plantadosi S, Eisenberger MA, Simons JH: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995, 1:944-949.
6. Sakurai T, Yangisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348:732-735.
7. Arai H, Hori S, Aramori I, Ohkubo H, Nakashii S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348:730-732.
8. Alexander SP, Mathie A, Peters JA: Endothelin. Br J Pharmacol 2006, 147 Suppl 3:S33-34.
9. Davar G, Hans G, Fareed MU, Sinnott C, Strichartz G: Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 1997, 9:2279-2283.
10. Davar G, Fareed MU, Pan HL, Hans G, Strichartz GR, Davar G: Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats. J Neurosci 2001, 21:5358-5366.
11. Raffa RB, Schupsky JJ, Jacoby HI: Characterization of endothelin-induced nociception in mice: evidence for a mechanistically distinct analgesic model. J Pharmacol Exp Ther 1999, 287:1-7.
12. Raffa RB, Schupsky JJ, Jacoby HI: Endothelin-induced nociception in mice: mediation by ETA and ETB receptors. J Pharmacol Exp Ther 1999, 287:647-651.
13. Ferreira SH, Romiti M, de Nucci G: Endothelin-1 participation in overt and inflammatory pain. J Cardiovasc Pharmacol 1989, 13 Suppl 5:S210-2.
14. Dahlof B, Gustafsson B, Hedin T, Jern S, Hansson L: Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens 1990, 8:811-817.
15. Davar G: Endothelin-1 and metastatic cancer pain. Pain Med 2001, 2:24-27.
16. Nicol GO: ET–phone the pain clinic. Trends Neurosci 2004, 27:177-80; discussion 180.
17. Pomonis JD, Rogers SD, Peters CM, Ghilardi JR, Mantyh PW: Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J Neurosci 2001, 21:999-1006.
18. Zhou QL, Strichartz G, Davar G: Endothelin-1 activates ET(A) receptors to increase intracellular calcium in model sensory neurons. Neuropeptides 2001, 35:383-387.
19. Yamamoto H, Kawamura T, Ninomiya T, Omoto K, Namiki A: Endothelin-1 enhances capsaicin-evoked intracellular Ca²⁺ response via activation of endothelin a receptor in a protein kinase C epsilon-dependent manner in dorsal root ganglion neurons. Neuroscience 2006, 137:949-960.
20. Zhou Z, Davar G, Strichartz G: Endothelin-1 (ET-1) selectively enhances the activation gating of slowly inactivating tetrodotoxin-resistant sodium currents in rat sensory neurons: a
mechanism for the pain-inducing actions of ET-1. J Neurosci 2002, 22:6325-6330.

21. Julius D, Bonica AJ: Molecular mechanisms of nociception. Nature 2001, 413:203-210.

22. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafolon J, Petersen- Zeit CK, Kolzenburg M, Basbaum AI, Julius D: Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000, 288:306-313.

23. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA: Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000, 405:183-187.

24. Plant TD, Zoller C, Mousa SA, Oksche A: Endothelin-1 potentiates capsaicin-induced TRPV1 currents via the endothelin A receptor. Exp Biol Med (Maywood) 2006, 231:161-1164.

25. Lokshere JC, Nicol GD: The CAMP transduction cascade mediates the proinflammatory E2 enhancement of the capsaicin-elicted current in rat sensory neurons: whole-cell and single-channel studies. J Neurosci 1998, 18:6081-6092.

26. Cesare P, McNaughton P: A novel heat-activated current in nociceptive neurons and its sensitization by bradykinin. Proc Natl Acad Sci U S A 1996, 93:3953-3958.

27. Sugita T, Tominaga M, Katsuya H, Mizzumura K: Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. J Neurophysiol 2002, 88:544-548.

28. Chung HH, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI, Chao MV, Julius D: Bradykinin and nerve growth factor factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001, 411:957-962.

29. Premkumar LS, Alhern GP: Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000, 408:985-990.

30. Tominaga M, Wada M, Masu M: Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci U S A 2001, 98:6951-6956.

31. Cesare P, Dekker LV, Gardin A, Parker PJ, McNaughton PA: Specific involvement of PKC-epsilon in the neuronal response to painful heat. Neuon 1999, 23:617-624.

32. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RW: CAMP-dependent protein kinase regulates desensitization of the TRPV1 receptor (VR1) by direct phosphorylation. Neuron 2002, 35:721-731.

33. Rathee PK, Distler C, Obreja O, Neuhuber W, Wang G, Wang SY, Nau C, Kress M: PKA/AKAP/VR1-1 module: A common link of Gs-mediated signaling to thermal hyperalgesia. J Neurosci 2002, 22:13419-13439.

34. Zhuang ZY, Xu H, Clapham DE, JI RR: Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J Neurosci 2004, 24:8300-8309.

35. Burrow-Mateus LN, Garovey CJ, Burke RM, Hall AK: Reduced expression of endothelin B receptors and mechanical hyperalgesia in experimental chronic diabetic. Exp Neurol 2006, 201:399-406.

36. Gunthorpe MJ, Smith GD, Davis JB, Randall AD: Characterisation of a human acid-sensing ion channel (hASIC1a) endogenously expressed in HEK293 cells. Pfugers Archiv European Journ of Physiology 2001, 442:668-674.

37. Aramori I, Nakainish I: Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells. J Biol Chem 1992, 267:12468-12474.

38. Oda K, Fujitani Y, Watake T, Inui T, Okada T, Uraje Y, Okuda-Ashitaka E, Ito S: Endothelin stimulates both CAMP formation and phosphatidylinositol hydrolysis in cultured embryonic bovine tracheal cells. FEBS Lett 1993, 329:299-303.

39. Eguchi S, Hiraiza Y, Marumo F: Endothelin subtypes B receptors are coupled to adenylate cyclase via inhibitory G protein in cultured bovine endothelial cells. J Cardiovasc Pharmacol 1993, 22 Suppl 8:S161-3.

40. Tomogami T, Toyooka H, Tominaga M: Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues. J Biol Chem 2002, 277:1337-13378.

41. Bhave G, Hu HJ, Glaudin W, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RW: Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc Natl Acad Sci U S A 2003, 100:12480-12485.

42. Bhatnagar DP, Nau C: Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J Biol Chem 2003, 278:50080-50099.

43. Mandadi S, Tominaga T, Numazaki M, Murayama N, Saito N, Armati PJ, Pagouilll BD, Tominaga M: Increased sensitivity of desensitized TRPV1 by PMA occurs through PKC epsilon-mediated phosphorylation at S800. Pain 2006, 123:106-116.

44. Moriyama T, Iida T, Kobayashi K, Higashi T, Fukuzoua T, Tsumura H, Leon C, Suzuki N, Inoue K, Gachet C, Noguchi K, Tominaga M: Possible involvement of P2Y2 metabotropic receptors in ATP-induced transient receptor potential vanilloid receptor 1-mediated thermal hypersensitivity. J Neurosci 2003, 23:6058-6062.

45. Zhang N, Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Caterina M, Oppenheim JJ: A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci U S A 2005, 102:4536-4541.

46. Sugita T, Bielefeldt K, Gehart GB: TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation. J Neurosci 2004, 24:9521-9530.

47. Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, Tominaga N, Narumiya S, Tominaga M: Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 2005, 1:13.

48. Prescott ED, Julius D: A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science 2003, 306:1284-1288.

49. Vellani V, Mapplebeck S, Moriondo A, Davis JB, McNaughton PA: Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol 2001, 534:813-825.

50. Morellina-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A: Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004, 279:25665-25672.

51. Burgess GM, Mullaney I, McNeill M, Dunn PM, Rang HP: Second messengers involved in the mechanism of action of bradyki- nin in sensory neurons in culture. J Neurosci 1989, 9:3314-3325.

52. Nicol GD, Cui M: Enhancement by prostaglandin E2 of bradykinin activation of embryonic rat sensory neurons. J Physiol 1994, 480:485-492.

53. Bandell M, Scory GM, Hwang SW, Viewawan V, Ed SR, Petrus MJ, Edley TJ, Patapoutian A: Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 2004, 41:849-857.

54. McCluskey EW, Gold MS: Ion channels of nociception. Annu Rev Physiol 1999, 61:835-856.

55. Lai J, Porreca F, Hunter JC, Gold MS: Voltage-gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol 2004, 44:371-397.

56. Gold MS, Levine JD, Correa AM: Modulation of TTX-R Ina by PKC and PKA and their role in PGE2-induced sensitization of rat sensory neurons in culture. J Neurosci 1989, 9:3314-3325.

57. Poizevan AP, D’Orleans-Juste P, Souza GE: Endothelin-1 induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultane- ous ET(B) receptor activation. Br J Pharmacol 2000, 129:461-968.

58. Fareed MU, Hans GH, Atanda A, Strichartz GR, Davar G: Pharmacological characterization of acute pain behavior produced by application of endothelin-1 to rat sciatic nerve. Journal of Pain 2000, 1:46-53.

59. Jarvis MF, Wessell JL, Zhu CZ, Lynch JH, Dayton BD, Calzadilla SV, Padley RJ, Oppegaard Tj, Kowaluk EA: ABT-627, an endothelin ETA receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur J Pharmacol 2000, 388:29-35.
61. Wacnik PW, Elkmeyer LJ, Ruggles TR, Rammairane ML, Walcheck BK, Beitz AJ, Wilcox GL: Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci 2001, 21:9355-9366.

62. Peters CM, Lindsay TH, Pomonis JD, Luger NM, Giilardi JR, Sevick MA, Mantyh PW: Endothelin and the tumorigenic component of bone cancer pain. Neuroscience 2004, 126:1043-1052.

63. Griswold DE, Douglas SA, Martin LD, Davis TG, Davis L, Ao Z, Luttmann MA, Pullen M, Nambi P, Hay DW, Ohlstein EH: Endothelin B receptor modulates inflammatory pain and cutaneous inflammation. Mol Pharmacol 1999, 56:807-812.

64. da Cunha JM, Rae GA, Ferreira SH, Cunha Fde Q: Endothelins induce ETB receptor-mediated mechanical hypernociception in rat hindpaw: roles of cAMP and protein kinase C. Eur J Pharmacol 2004, 501:87-94.

65. De-Melo JD, Tonussi CR, D'Orleans-Juste P, Rae GA: Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat: inhibition by endothelin receptor antagonists. Pain 1998, 77:261-269.

66. Baamonde A, Lastra A, Villazon M, Bordallo J, Hidalgo A, Menendez L: Involvement of endogenous endothelins in thermal and mechanical inflammatory hyperalgesia in mice. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:245-251.

67. Balonov K, Khodorova A, Strichartz GR: Tactile allodynia initiated by local subcutaneous endothelin-1 is prolonged by activation of TRPV-1 receptors. Exp Biol Med (Maywood) 2006, 231:1165-1170.

68. Khodorova A, Navarro B, Jouaville LS, Murphy JE, Rice FL, Mazurkiewicz JE, Long-Woodward D, Stoffel M, Strichartz GR, Yukihananov R, Dava G: Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med 2003, 9:1055-1061.

69. Zollner C, Shaqura MA, Bopaiah CP, Mousa S, Stein C, Schafer M: Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons. Mol Pharmacol 2003, 64:202-210.

70. Hellwig N, Albrecht N, Harteneck C, Schultz G, Schaefner M: Homo- and heteromeric assembly of TRPV channel subunits. J Cell Sci 2005, 118:917-928.

71. Gregan B, Jurgensen J, Papsdorf G, Farkert J, Schaefer M, Beyermann M, Rosenthal W, Okache A: Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 2004, 279:27679-27687.

72. Grancharova E, Farkert J, Reusch HP, Krell HW, Papsdorf G, Beyermann M, Schulein R, Rosenthal W, Okache A: The extracellular N terminus of the endothelin B (ETB) receptor is cleaved by a metalloprotease in an agonist-dependent process. J Biol Chem 2002, 277:43933-43941.

73. Olschke A, Boese G, Horstmeyer A, Farkert J, Beyermann M, Bienert M, Rosenthal W: Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Mol Pharmacol 2000, 57:1104-1113.

74. Olschke A, Boese G, Horstmeyer A, Papsdorf G, Farkert J, Beyermann M, Bienert M, Rosenthal W: Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Mol Pharmacol 2000, 57:1104-1113.

75. Stromann R, Harteneck C, Nunnenmacher K, Schultz G, Plunt TD: OTRPC4, a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat Cell Biol 2000, 2:695-702.